Nationwide Fund Advisors cut its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 3.0% during the third quarter, according to its most recent filing with the SEC. The fund owned 69,549 shares of the company’s stock after selling 2,122 shares during the period. Nationwide Fund Advisors owned 0.19% of bluebird bio worth $4,714,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of BLUE. Vanguard Group Inc. boosted its stake in bluebird bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock valued at $116,055,000 after buying an additional 333,396 shares during the last quarter. Swiss National Bank boosted its stake in bluebird bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter. RS Investment Management Co. LLC boosted its stake in bluebird bio by 9.0% in the second quarter. RS Investment Management Co. LLC now owns 575,093 shares of the company’s stock valued at $24,896,000 after buying an additional 47,339 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in bluebird bio by 43.0% in the second quarter. JPMorgan Chase & Co. now owns 85,235 shares of the company’s stock valued at $3,690,000 after buying an additional 25,612 shares during the last quarter. Finally, Schroder Investment Management Group purchased a new stake in bluebird bio during the second quarter valued at $1,092,000.

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 2.64% during trading on Friday, reaching $67.95. 276,729 shares of the company were exchanged. The company’s 50-day moving average is $66.38 and its 200 day moving average is $57.78. The firm’s market capitalization is $2.53 billion. bluebird bio, Inc. has a 1-year low of $35.37 and a 1-year high of $79.70.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.59) by $0.48. The company earned $1.55 million during the quarter, compared to the consensus estimate of $1.82 million. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. bluebird bio’s revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.18) earnings per share. Equities research analysts expect that bluebird bio, Inc. will post ($7.02) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) Stake Decreased by Nationwide Fund Advisors” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright law. The legal version of this piece of content can be read at http://www.dailypolitical.com/2017/01/13/bluebird-bio-inc-blue-stake-decreased-by-nationwide-fund-advisors.html.

BLUE has been the topic of several research reports. Roth Capital initiated coverage on bluebird bio in a research report on Thursday, September 22nd. They set a “buy” rating and a $87.00 price objective on the stock. Goldman Sachs Group, Inc. (The) raised bluebird bio from a “buy” rating to a “conviction-buy” rating and set a $135.00 price objective on the stock in a research report on Thursday, September 15th. Cantor Fitzgerald cut bluebird bio from a “hold” rating to a “sell” rating and cut their price objective for the company from $65.24 to $37.00 in a research report on Friday, October 14th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $120.00 price objective on shares of bluebird bio in a research report on Wednesday, December 7th. Finally, Leerink Swann lifted their price objective on bluebird bio from $67.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday, October 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio currently has an average rating of “Buy” and an average target price of $85.60.

In other bluebird bio news, insider Jason Cole sold 549 shares of the company’s stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $67.10, for a total value of $36,837.90. Following the transaction, the insider now directly owns 9,389 shares in the company, valued at approximately $630,001.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is currently owned by company insiders.

bluebird bio Company Profile

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.